Read by QxMD icon Read


Wenqin Yue, Bin Liu, Lei Gao, Miaoxia He, Jianmin Wang, Weiping Zhang, Li Chen, Xiaoxia Hu, Lili Xu, Jianmin Yang
BACKGROUND: The pretreatment albumin to globulin ratio (AGR) has been used to predict survival in several types of tumors. However, whether AGR can predict outcomes in patients with diffuse large B-cell lymphoma (DLBCL) remains unclear. We evaluated the prognosis value of AGR in DLBCL patients. METHODS: We retrospectively analyzed the available serum biochemical results of 335 patients with newly diagnosed DLBCL before treatment. The AGR was calculated as: albumin (g/L)/globulin...
July 10, 2018: Clinica Chimica Acta; International Journal of Clinical Chemistry
Ruimin Wang, Baixuan Xu, Changbin Liu, Zhiwei Guan, Jinming Zhang, Fei Li, Lu Sun, Haiyan Zhu
OBJECTIVE: To examine the prognostic value of fluorodeoxyglucose (FDG) and fluorothymidine (FLT) interim positron emission tomography/computed tomography (PET/CT) for diffuse large B cell lymphoma (DLBCL). METHODS: Forty-four patients with newly diagnosed DLBCL underwent both 18F-FDG and 18F-FLT PET/CT scans at baseline and after two cycles of a rituximab-containing chemotherapy regimen. Maximum standard uptake values (SUVmax) and changes in SUV (ΔSUV) were calculated for both tracers for the predominant lesion of each patient, for prediction of progression free survival (PFS) and overall survival (OS)...
July 13, 2018: British Journal of Radiology
Y Qin, P Liu, J L Yang, J Jin, X H He, W H Wang, H Fang, S Y Zhou, L Q Zhou, Y W Song, Y K Shi
Objective: Primary gastric diffuse large B-cell lymphoma (PG-DLBCL) is the most common non-Hodgkin lymphoma (NHL) of extranodal origin. Most patients with PG-DLBCL had localized disease (stage Ⅰ or Ⅱ) at presentation, and will achieve complete response (CR) after induction chemotherapy. However, there has been little consensus regarding whether optimal treatment is provided by chemotherapy alone or chemotherapy plus radiotherapy, nor the treatment outcome from the addition of rituximab in localized-stage PG-DLBCL...
June 26, 2018: Zhonghua Yi Xue za Zhi [Chinese medical journal]
Zijian Liu, Jingshu Meng, Xiaoqian Li, Fang Zhu, Tao Liu, Gang Wu, Liling Zhang
There is a significant difference in prognosis between the germinal center B-cell (GCB) and activated B-cell (ABC) subtypes of diffuse large B-cell lymphoma (DLBCL). However, the signaling pathways and driver genes involved in these disparate subtypes are ambiguous. This study integrated three cohort profile datasets, including 250 GCB samples and 250 ABC samples, to elucidate potential candidate hub genes and key pathways involved in these two subtypes. Differentially expressed genes (DEGs) were identified...
2018: BioMed Research International
Shaoying Li, Pei Lin, L Jeffrey Medeiros
The designation high-grade B-cell lymphoma (HGBL) has been incorporated into the 2016 Revision of the WHO classification of lymphoid neoplasms and includes two types: (1) HGBL, not otherwise specified; and (2) HGBL with MYC and BCL2 and/or BCL6 rearrangements, also known as double or triple hit lymphoma (DHL/THL). These categories of lymphomas represent 1-2% of non-Hodgkin lymphomas and a considerable portion of DLBCL patients who are primary refractory to R-CHOP therapy. It corresponds to the designation 'B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma' in the 2008 WHO classification...
July 10, 2018: Expert Review of Hematology
Dai Chihara, Nathan H Fowler, Yasuhiro Oki, Michelle A Fanale, Loretta J Nastoupil, Jason R Westin, Luis E Fayad, Sattva S Neelapu, Chan Yoon Cheah
Primary central nervous system lymphoma (PCNSL) is a rare and aggressive extranodal presentation of lymphoma; however, the data for outcomes of patients with subtypes other than diffuse large B-cell lymphoma (DLBCL) are limited. Therefore, we analyzed overall survival (OS) of adult patients diagnosed with PCNSL by histologic subtype between 1998 and 2014 using the Surveillance, Epidemiology and End Results. A total of 4375 patients were identified. The median age of the patients was 64 years (range: 18-96)...
June 22, 2018: Oncotarget
Jorge J Castillo, Brady E Beltran, Roberto N Miranda, Ken H Young, Julio C Chavez, Eduardo M Sotomayor
DISEASE OVERVIEW: Epstein Barr virus-positive (EBV+) diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) is an entity included in the 2016 WHO classification of lymphoid neoplasms. EBV+ DLBCL, NOS, is an aggressive B-cell lymphoma associated with chronic EBV infection, and a poor prognosis with standard chemotherapeutic approaches. DIAGNOSIS: The diagnosis is made through a careful pathological evaluation. Detection of EBV-encoded RNA is considered standard for diagnosis; however, a clear cutoff for positivity has not been defined...
July 2018: American Journal of Hematology
Akihiro Yoshimura, Taisuke Tsuji, Yuka Kawaji, Yoshiko Hirakawa, Hitoji Uchiyama, Noriya Hiraoka
The patient, a 70-year-old woman with diffuse large B-cell lymphoma (DLBCL), developed haemorrhagic cystitis associated with the BK virus (BKV) and adenovirus type 11. Moreover, chest computed tomography showed ground-glass opacity (GGO) in the bilateral upper lobe, and we performed bronchoalveolar lavage (BAL). The BKV DNA load was elevated not only in blood but also in BAL fluid (BALF), leading to the diagnosis of BKV pneumonia. After administering cidofovir, the respiratory symptoms and GGO abated. Therefore, detection of BKV DNA in BALF is useful for diagnosing BKV pneumonia...
October 2018: Respirology Case Reports
Telma Murias Dos Santos, Juan Pablo Zumárraga, Fábio Mazetti Reaes, Carlos Henrique Maçaneiro, André Mathias Baptista, Olavo Pires DE Camargo
Objective: It is difficult to define parameters for management and factors associated with primary bone lymphoma (PBL). This article presents the experience in a single institution with 42 patients with PBL over a 16-year period (2000-2016). Methods: Fifty-five patients were retrospectively evaluated, and forty-two were included (76.3%). Results: Median age at diagnosis was 51.5 years, and median follow-up was 102.7 months. One patient had HIV...
March 2018: Acta Ortopedica Brasileira
Linyu Li, Xuhan Zhang, Tingting Zhang, Zheng Song, Ge Hu, Wei Li, Lanfang Li, Lihua Qiu, Zhengzi Qian, Shiyong Zhou, Xianming Liu, Lixia Feng, Yi Pan, Qiongli Zhai, Bin Meng, Xiubao Ren, Kai Fu, Ping Wang, Xianhuo Wang, Huilai Zhang
BACKGROUND: Double-expression lymphoma (DEL) is a rare subgroup of diffuse large B-cell lymphoma (DLBCL), which has coexpression of MYC and BCL-2. Coexpression of MYC and BCL-2 is considered a prognostic marker portending poor outcomes. However, the prognostic effect of BCL-2 and BCL-6 expression in DLBCL remains controversial. MATERIALS AND METHODS: Immunohistochemical staining was performed to detect MYC, BCL-2 and BCL-6 expression in 212 patients with newly diagnosed DLBCL and assess the prognostic effects of BCL-2 and BCL-6 expression...
June 19, 2018: Clinical Lymphoma, Myeloma & Leukemia
Carlos Montalbán, Antonio Díaz-López, Alejandro Martín, Mónica Baile, José M Sanchez, Juan M Sancho, Olga García, Silvana Novelli, Anna Monter-Rovira, Antonio Salar, Mariana Bastos, Antonio Gutiérrez, Leyre Bento, Raul Córdoba, Teresa Arquero, Sonia González de Villambrosia, Gilberto Barranco, Raquel De Oña, Armando López Guillermo, María J Rodriguez Salazar, Juan F Domínguez, Rubén Fernández, José A Queizan, José Rodríguez, Victor Abraira, Juan F García
The Grupo Español de Linfomas y Trasplantes de Médula Ósea International Prognostic Index (GELTAMO-IPI) stratifies four risk groups in diffuse large B cell lymphoma (DLBCL) patients treated with immunochaemotherapy: low (LR), low-intermediate (LIR), high-intermediate (HIR), and high (HR). The present study explores the effect of GELTAMO-IPI in the DLBCL subtypes defined by the immunohistochaemistry-based Hans algorithm, Germinal Centre B (GCB) and non-GCB. A multivariate Cox regression model including GELTAMO-IPI risk groups, cell of origin (COO) subtypes and their product was developed to evaluate interaction between the two variables...
July 5, 2018: British Journal of Haematology
Mubarak M Al-Mansour, Saif A Alghamdi, Musab A Alsubaie, Abdullah A Alesa, Muhammad A Khan
Background: Hepatitis B virus (HBV) is one of the most prevalent and serious infections worldwide. HBV reactivation is a serious complication for lymphoma patients who are being treated with rituximab-containing regimen. Since the impact of HBV has not been fully evaluated on the prognosis of diffuse large B cell lymphoma (DLBCL), this study examined the effect of the hepatitis infection on the progression-free survival (PFS) and overall survival (OS) in patients with DLBCL who received rituximab-containing chemotherapy...
2018: Infectious Agents and Cancer
Céline Bouvy, Adeline Wannez, Fabienne George, Carlos Graux, Christian Chatelain, Jean-Michel Dogné
Objectives: Diffuse large B-cell lymphoma (DLBCL) is highly heterogeneous in terms of phenotype and treatment response in patients. These characteristics make the prognosis difficult to establish and hinder the use of new personalized treatments in clinical practice. In this context, there is currently a need to define new biomarkers enabling a better definition of DLBCL subtypes, prognosis evaluation, and an overview of the resistance to chemotherapeutics. The aim of this study was to evaluate the use of microRNAs found in plasma from patients with DLBCL as biomarkers of tumor evolution in these patients...
2018: Biomarkers in Cancer
Qian Shi, Norbert Schmitz, Fang-Shu Ou, Jesse G Dixon, David Cunningham, Michael Pfreundschuh, John F Seymour, Ulrich Jaeger, Thomas M Habermann, Corinne Haioun, Hervé Tilly, Hervé Ghesquieres, Francesco Merli, Marita Ziepert, Raoul Herbrecht, Jocelyne Flament, Tommy Fu, Bertrand Coiffier, Christopher R Flowers
Purpose Overall survival (OS) is the definitive and best-established primary efficacy end point to evaluate diffuse large B-cell lymphoma (DLBCL) therapies, but it requires prolonged follow-up. An earlier end point assessed post-treatment would expedite clinical trial conduct and accelerate patient access to effective new therapies. Our objective was to formally evaluate progression-free survival (PFS) and PFS at 24 months (PFS24) as surrogate end points for OS in first-line DLBCL. Patients and Methods Individual patient data were analyzed from 7,507 patients from 13 multicenter randomized controlled trials of active treatment in previously untreated DLBCL, published after 2002, with sufficient PFS data to predict treatment effects on OS...
July 5, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
Parag Mahale, Eric A Engels, Jill Koshiol
Hepatitis B virus (HBV) infection causes hepatocellular carcinoma (HCC). Associations with other cancers are not established. We systematically assessed associations between HBV infection and cancers in the US elderly population. We conducted a case-control study using the Surveillance, Epidemiology, and End Results (SEER)-Medicare database in US adults aged ≥66 years. Cases (N=1,825,316) were people with first cancers diagnosed in SEER registries (1993-2013). Controls (N=200,000) were randomly selected, cancer-free individuals who were frequency-matched to cases on age, sex, race, and calendar year...
July 4, 2018: International Journal of Cancer. Journal International du Cancer
Zai-Sheng Chen, Yong-Zhi Zheng, Yi-Qiao Chen, Qin-Li Gao, Jian Li, Jian-Zhen Shen
OBJECTIVE: To study the clinical features and treatment outcome of children with mature B-cell non-Hodgkin's lymphoma (B-NHL). METHODS: A total of 28 previously untreated children with mature B-NHL were enrolled and given the chemotherapy regimen of CCCG-B-NHL-2010. Among them, 20 were given rituximab in addition to chemotherapy. The children were followed up for 31 months (ranged 4-70 months). A retrospective analysis was performed for the clinical features of these children...
June 2018: Zhongguo Dang Dai Er Ke za Zhi, Chinese Journal of Contemporary Pediatrics
Xinyao Li, Zhengchang He, Bingqing Cheng, Qin Fang, Dan Ma, Tingting Lu, Danna Wei, Xingyi Kuang, Sishi Tang, Jie Xiong, Jishi Wang
Diffuse large B-cell lymphoma (DLBCL) is the most common type of adult lymphoma. It is a group of malignant tumors with a large number of clinical manifestations and prognoses. Therefore, it is necessary to explore its unknown potential therapeutic targets. Histone deacetylase inhibitor (HDACi) is a novel drug for the treatment of DLBCL, however pan-HDACis cannot be ignored because of their clinical efficacy. By contrast, specific HDACi is well-tolerated, and LMK-235 is a novel HDACi that is a specific inhibitor of HDAC4 and HDAC5...
July 3, 2018: Cancer Biology & Therapy
Amy Starr, Dong Hyang Kwon, Bhaskar Kallakury
Diffuse large B-cell lymphoma (DLBCL) is characterized by medium- to large-sized neoplastic cells that express a wide range of B-cell markers including CD19, CD20, CD22, and CD79a. Also, as this is a hematopoietic malignancy, there is expression of the leukocyte common antigen CD45. Lack of CD20 expression occurs in a specific rare heterogeneous subgroup of DLBCL including primary effusion lymphoma, plasmablastic lymphoma, ALK-positive large B-cell lymphoma, and large B-cell lymphoma arising in HHV8+ multicentric Castleman disease...
June 1, 2018: International Journal of Surgical Pathology
Keishi Makino, Hideo Nakamura, Naoki Shinojima, Jun-Ichiro Kuroda, Shigetoshi Yano, Yoshiki Mikami, Akitake Mukasa
PURPOSE: Primary central nervous system diffuse large B-cell lymphoma (CNS-DLBCL) is a distinct clinicopathological entity with a poor prognosis. Concurrent MYC and BCL2 overexpression predicts inferior prognosis in systemic DLBCL, although their prognostic significance remains unclear in primary CNS-DLBCL. METHODS: Pretreatment diagnostic biopsy samples were retrospectively evaluated for 79 patients with primary CNS-DLBCL who were treated between January 2001 and December 2017...
July 2, 2018: Journal of Neuro-oncology
Thomas Yssing Michaelsen, Julia Richter, Rasmus Froberg Brøndum, Wolfram Klapper, Hans Erik Johnsen, Mads Albertsen, Karen Dybkær, Martin Bøgsted
Gene expression profiling (GEP) by microarrays of diffuse large B-cell lymphoma (DLBCL) has enabled the categorization of DLBCL into activated B-cell-like and germinal center B-cell-like subclasses. However, as this does not fully embrace the great diversity of B-cell subtypes, we recently developed a gene expression assay for B-cell-associated gene signature (BAGS) classification. To facilitate quick and easy-to-use BAGS profiling, we developed in this study the NanoString-based BAGS2Clinic assay. Microarray data from 4 different cohorts (n = 970) were used to select genes and train the assay...
July 10, 2018: Blood Advances
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"